Quarterly Earnings Analysis - Report on Pfizer

NEW YORK, September 15, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Pfizer Inc. (NYSE: PFE). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/reports?keyword=PFE  

Highlights from our PFE Report include:

• Top-line Performance Review - On July 28, 2015, the US based pharmaceutical company, Pfizer Inc. announced results for the second quarter ended June 2015. Revenue declined 7% or by $920 million to $11.9 billion in Q2 2015, compared to $12.8 billion in the year-ago period. As per a same day Reuters report, consensus analyst at Wall street expected revenues of $11.42 billion for the quarter. In Q2 2015, the Company's operational revenue growth in developed markets got a boost by healthy performance of several key products. Prevnar 13 in adults, Eliquis, Ibrance and Xeljanz are some of these products to name a few. Reflecting sustained strong operational growth, primarily from Lipitor and Prevenar 13, revenue from operations grew by 6% in emerging markets.

• Innovative Products Business Performance - The Innovative Products Business recorded a revenue growth of 17% operationally, driven by higher revenues from the Global Innovative Pharmaceutical (GIP) and the Global Vaccines, Oncology and Consumer Healthcare (VOC) segments. While revenue from GIP grew 8% operationally, VOC showcased a strong growth of 29% operationally in Q2 2015. Strong operational performance from GIP was on the back of recent product launches, including Eliquis globally and Xeljanz in the US, coupled with impressive performance of Lyrica in the US and Japan and Viagra in the US. Within VOC, the Global Vaccine business saw a 52% operationally and Global Oncology business registered a growth of 36% operationally while Consumer Healthcare revenues declined 2% operationally.

• Established Products Business Performance - The Global Established Pharmaceutical (GEP) segment reported a 14% decline in revenues operationally. The Company further informed that the decline in revenue from GEP was due to the loss of exclusivity and immediate launch of multi-source generic competition for Celebrex in the US in December 2014, as well as generic competition for Zyvox in the US beginning in first-half 2015, and for Lyrica in certain developed Europe markets beginning in first-quarter 2015.

• Bottom-line Performance & Outlook - Net income attributable to Pfizer was 2.6 billion, down 9.8% from 2.9 billion in the prior year quarter. Consequently, diluted earnings per share declined to $0.42 from $0.45 per share in second quarter ended June 2014. Second-Quarter 2015 adjusted Diluted EPS was $0.56, which as per the Reuters report, exceeded analysts' average expectations by 4 cents a share. For the full year 2015, the Company expects revenues to be in $45.0 to $46.0 billion range, compared to the previous guidance of $44.0 to $46.0 billion.

To find out how this influences our rating on Pfizer Inc., read the full report in its entirety here: http://www.aciassociation.com/reports?keyword=PFE

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com